ArticleBMC research notes2020
Prevalence of multi-drug resistant (MDR) and extensively drug-resistant (XDR) phenotypes of Pseudomonas aeruginosa and Acinetobacter baumannii isolated in clinical samples from Northeast of Iran.
Article in BMC research notes, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed, 4 syntheses or guidelines pooled it, 145 citations in OpenAlex.
- An insight into the antibiotic resistance profiles of ESKAPE pathogens isolated from humans in Africa: a systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
- Antibiotic resistance and bacterial co-infections in COVID-19 patients in Iran: a systematic review and meta-analysis of hospitalized and non-hospitalized cases.BMC infectious diseases · 2025Pooled it
- Worldwide threatening prevalence of carbapenem-resistantEpidemiology and infection · 2025Pooled it
- Geographical mapping and temporal trends of Acinetobacter baumannii carbapenem resistance: A comprehensive meta-analysis.PloS one · 2024Pooled it
- Antimicrobial resistance profiles of ESKAPE pathogens isolated in a microbiology laboratory in Somalia: a two-year retrospective study.BMC infectious diseases · 2026Article
- Liposomal antimicrobials in the fight against bacterial and fungal pathogens: Clinical successes and development challenges.International journal of pharmaceutics: X · 2026Review
- Antibiotic Resistance and Biofilm Gene Distribution in Colistin-Resistant Acinetobacter baumannii.MicrobiologyOpen · 2026Article
- Comparative genomic surveillance of carbapenem-resistantMicrobiology spectrum · 2026Article
- The threat of multidrug-resistant microorganisms: active surveillance of key antimicrobial resistant pathogens in 2025 - a report from the INVIFAR network.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Optimized green zinc oxide/chitosan/amoxicillin nanocomposite against Pseudomonas aeruginosa.Applied microbiology and biotechnology · 2026Article
- Synergistic effects of meropenem, amikacin, and ciprofloxacin against carbapenem resistant Pseudomonas aeruginosa isolates.Scientific reports · 2026Article
- Article
- Detection of Toxin Genes and Biofilm Formation ofInternational journal of microbiology · 2026Article
- High-dose aztreonam potentiates the combined antimicrobial activity of ceftazidime-avibactam against extensively drug-resistant New Delhi metallo-β-lactamase positiveFrontiers in cellular and infection microbiology · 2026Article
- Potential of Eugenia brejoensis (Mazine) Essential Oil in Combating Multidrug-Resistant (MDR) Acinetobacter baumannii and Pseudomonas aeruginosa.Chemistry & biodiversity · 2026Article
- Comparison of antibiotic resistance, virulence determinants, and biofilm formation in Pseudomonas aeruginosa isolated from intestinal carriers and clinical samples.Folia microbiologica · 2025Article
- Draft genomes of multidrug-resistantMicrobiology resource announcements · 2025Article
- Bioprospecting Heavy-Metal Rhizospheres for Novel Therapeutics Against High-Priority Multi-Drug-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii: A Case of Toxic to Treatment.Environmental microbiology reports · 2025Article
- Rosemary Extract: Phytochemical Composition and Potential for Eliminating Polymicrobial Biofilm ofBiotech (Basel (Switzerland)) · 2025Article
- Activity of cefiderocol on extensively drug-resistantIranian journal of microbiology · 2025Article
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveMulti and extensively drug-resistant (MDR and XDR), Pseudomonas aeruginosa (P. aeruginosa) and Acinetobacter baumannii (A. baumannii) are two main causative agents of nosocomial infections leading to increased morbidity and mortality. We aim to study the prevalence of MDR and XDR-A. baumannii and P. aeruginosa phenotypes in clinical specimens. We conducted this for 1 year (2017-2018) and isolated bacteria from the clinical samples. Then, XDR and MDR strains were determined by susceptibility testing (disc diffusion).
resultsOut of 3248 clinical samples, A. baumannii and P. aeruginosa strains were detected in 309(9.51%) of them. Susceptibility testing indicated that (16.50%) and (15.53%) of the P. aeruginosa and (74.75%) and (73.13%) of the A. baumannii isolates were screened as the MDR and XDR strains. The frequency of MDR isolates was higher in wound samples 222 (71.8%). This rate in behavioral intensive care unit (BICU) and restoration ward, were 187 (60.5%) and 63 (20.4%). The frequency of XDR isolates in BICU 187 (59.54%), restoration 58(18.77%), and burns 30 (9.70%) were assessed as well. Considering high isolation rates of MDR and XDR of mentioned strains, it is necessary to apply prevention criteria for eradication of the mentioned bacteria from hospital wards.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.